OUR COMPANY
OUR TECHNOLOGY
SOLUTIONS
PARTNERSHIPS
RESEARCH & EVIDENCE
IN THE NEWS
HOW IT WORKS
INVEST
CONTACT US
INVEST
RESEARCH & EVIDENCE
Host response to immune checkpoint inhibitors contributes to tumor aggressiveness
Read More >
A proteomic biomarker discovery platform for predicting clinical benefit of immunotherapy in advanced melanoma
Read More >
The pro-tumorigenic host response to cancer therapies
Read More >
A proteomics-based biomarker discovery platform for predicting clinical response to immune checkpoint inhibitor therapy in non-small cell lung cancer
Read More >
21 Plasma-based proteomic profiling as a tool for predicting response to immunotherapy in melanoma patients
Read More >
Proteomics of Microparticles with SILAC Quantification (PROMIS-Quan): A Novel Proteomic Method for Plasma Biomarker Quantification
Read More >
Host effects contributing to cancer therapy resistance
Read More >